# SANA — replay s5 — bf16

## Metadata

ticker: SANA
arm: bf16
sample: 5
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/SANA_local-model.md
context_sha256: 03e6bdab74ad2102adf024d5f44d8c25f69c6ba19acc4870607d569ceca09ae2
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:48:58Z
financial_health_prompt_sha256: 0a7f61736a0b9867773ff7db9508225e9a13499f7330cee4b00e8cebbb7ed76d
financial_health_seed: 1050270
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 123
risk_factors_prompt_sha256: f9aa231716879b9188636cec364f613a0e910dd13e3e5de132fec68b9fe09366
risk_factors_seed: 1050271
risk_factors_response_model: financial-lora
risk_factors_finish_reason: length
risk_factors_completion_tokens: 512

## Stock data

{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 3.08,
  "currency": "USD",
  "market_cap": 922030720.0,
  "forward_pe": -5.54845,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "net_income": -211822000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health
Sana Biotechnology, Inc., trades under the ticker symbol SANA. It is headquartered in [Insert Location Here].]
The company carries a current market capitalization of $92.2 billion (in USD), as reported on March 3, 2026.]
It reports net income of -$21.2 billion (in USD), as reported on March 3, 2026.)
The company's net income per share is -$2.12 per share (in USD), as reported on March 3, 2026.)

<!-- replay-section: Risk Factors -->
### Primary Risk Factors Disclosed

The company faces various material risks, which can be categorized into several key areas:

#### 1. **Technology and Development Risks**
   - The company relies on novel, unproven technologies for its cell engineering platforms. These technologies may not prove successful in identifying, developing, and commercializing product candidates.
   - The company’s preclinical testing is subject to substantial uncertainty. If the company fails to successfully identify, develop, and commercialize product candidates, it will experience significant delays in doing so.
   - The company’s clinical trials are also subject to substantial uncertainty. If the company experiences significant delays in conducting clinical trials, or if the results of such trials do not support the initiation of further clinical trials, the company will experience significant delays in doing so.
   - The company’s clinical trials may also be subject to other uncertainties, including those relating to the timing and conduct of such trials, the interpretation of data generated during such trials, and the availability of any necessary regulatory approvals.

#### 2. **Financial and Operational Risks**
   - The company faces substantial doubt regarding its ability to continue as a going concern. This uncertainty may adversely affect the value of the company’s securities.
   - The company requires substantial additional funds to finance its operations, including the continued development and commercialization of product candidates. It is possible that the company will not be able to obtain sufficient additional financing when needed or at all. If the company is unable to obtain adequate financing on acceptable terms, it may be forced to delay, reduce, or eliminate certain research and development activities, product development programs, and commercialization efforts. Such actions would likely have a material adverse effect on the company’s financial condition and operating results.

#### 3. **Personnel and Strategic Risks**
   - The company depends on the services of key personnel, including executive officers, directors, senior management, and other employees. The loss of the services of one or more of these individuals could have a material adverse effect on the company’s business, financial condition, and operating results.
   - The company also relies on the services of consultants and advisors who provide expertise and advice in connection with the company’s business strategy, product development plans, and marketing initiatives. The loss of the services of one or more of these individuals could have a material adverse effect on the company’s business, financial condition, and operating results.
   - The company also relies on the services of independent contractors and vendors who perform work on behalf of the company. The loss of the services of
